Saturday, 17 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

ALMUNDA PRO NV Stock Impressive Jump On Wednesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with ALMUNDA PRO NV (AMUND.AS) jumping 20.3% to €1.60 on Wednesday while AEX-Index fell 1.55% to €754.13.

ALMUNDA PRO NV's last close was €1.33, 14.19% under its 52-week high of €1.55.

About ALMUNDA PRO NV

Almunda Professionals N.V., a business and IT consultancy company, provides business services in the financial sector. It offers consultancy services in the areas of regulatory change, digital transformation, information security, and information services. The company was formerly known as Novisource N.V. and changed its name to Almunda Professionals N.V. in August 2021. Almunda Professionals N.V. was founded in 2001 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ALMUNDA PRO NV has a trailing twelve months EPS of €0.02.

PE Ratio

ALMUNDA PRO NV has a trailing twelve months price to earnings ratio of 80. Meaning, the purchaser of the share is investing €80 for every euro of annual earnings.

More news about ALMUNDA PRO NV (AMUND.AS).

Categories

stockMarket

Tags

AMUND.ASMarket-Close NowStock PriceClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpStock MarketStockALMUNDA PRO NV
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com